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Background Endometrial biopsies are undertaken in
premenopausal women with abnormal uterine bleeding but the
risk of endometrial cancer or atypical hyperplasia is unclear.
Objectives To conduct a systematic literature review to establish
the risk of endometrial cancer and atypical hyperplasia in
premenopausal women with abnormal uterine bleeding.
Search strategy Search of PubMed, Embase and the Cochrane
Library from database inception to August 2015.
Selection criteria Studies reporting rates of endometrial cancer
and/or atypical hyperplasia in women with premenopausal
abnormal uterine bleeding.
Data collection and analysis Data were independently extracted by
two reviewers and cross-checked. For each outcome, the risk and
a 95% CI were estimated using logistic regression with robust
standard errors to account for clustering by study.
Main results Sixty-five articles contributed to the analysis. Risk of
endometrial cancer was 0.33% (95% CI 0.23–0.48%, n = 29 059; 97
cases) and risk of endometrial cancer or atypical hyperplasia was
1.31% (95% CI 0.96–1.80, n = 15 772; 207 cases). Risk of
endometrial cancer was lower in women with heavy menstrual
bleeding (HMB) (0.11%, 95% CI 0.04–0.32%, n = 8352; 9 cases)
compared with inter-menstrual bleeding (IMB) (0.52%, 95% CI
0.23–1.16%, n = 3109; 14 cases). Of five studies reporting the rate of
atypical hyperplasia in women with HMB, none identified any cases.
Conclusions The risk of endometrial cancer or atypical hyperplasia
in premenopausal women with abnormal uterine bleeding is low.
Premenopausal women with abnormal uterine bleeding should
first undergo conventional medical management. Where this fails,
the presence of IMB and older age may be indicators for further
investigation. Further research into the risks associated with age
and the cumulative risk of co-morbidities is needed.
Keywords Biopsy, endometrial neoplasms, premenopause, risk,
systematic review.
Tweetable abstract Contrary to practice, premenopausal women
with heavy periods or inter-menstrual bleeding rarely require
biopsy.
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Introduction
Endometrial cancer has a world-wide incidence of 9 per
100 000 women, with a 1% lifetime risk.1 Most cases are in
women aged >50 years.1 Unopposed oestrogen exposure is
a significant risk factor,2 where prolonged exposure causes
continual endometrial proliferation and, potentially,
endometrial carcinoma.2 Other factors influencing oestro-
gen exposure include obesity, polycystic ovarian syndrome
(PCOS), anovulation, nulliparity, and type 2 diabetes melli-
tus3 and these are also thought to increase the risk of
endometrial cancer. Endometrial hyperplasia, that is,
irregular proliferation of the endometrial glands, may, in
some cases, be a precursor to endometrial cancer. ‘Atypical’
hyperplasia poses the highest risk and, as with endometrial
cancer, is managed with hysterectomy.4
Endometrial cancer most commonly presents with post-
menopausal bleeding (PMB).3 It is therefore recommended
that women presenting with PMB are referred for further
investigation.5,6 Premenopausal abnormal uterine bleeding
is common and estimated to interfere with daily life in
more than one-fifth of women.7 However, the current evi-
dence base on premenopausal abnormal uterine bleeding
and the risk of endometrial cancer is unclear.8 The
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Systematic review
selection of possible indicators for biopsy to exclude
endometrial cancer is contentious9 and current guidance
varies. All guidelines appear to recommend an age cutoff,
above which patients are referred; in some it is 4010,11 and
in others it is 45 years.12,13 All identify IMB as an indica-
tion for biopsy, and some also recommend biopsy based
on other risk factors, such as obesity or PCOS.13,11 In
some, such as the UK National Institute for Health and
Care Excellence (NICE) guideline, it is recommended that
biopsy should only be undertaken when conventional med-
ical management has failed,12 whereas other guidance rec-
ommends direct referral for biopsy in higher risk (e.g.
older) patients with abnormal uterine bleeding.10,11,13
In the UK, despite the NICE guideline, it is unclear
whether all premenopausal women with abnormal uterine
bleeding complete conventional management before referral
for biopsy, or whether women considered ‘high risk’ are
directly referred. Although guidelines, including the UK
NICE guideline, were underpinned by some research evi-
dence, none appears to have been based on a comprehen-
sive literature review and there has been no other
systematic review examining the risk of endometrial malig-
nancy in this group. The aim of this work was therefore to
conduct a systematic review to establish the risk of
endometrial cancer and atypical hyperplasia in women with
abnormal uterine bleeding and to make some judgment
about the relative validity of current guidelines.
Methods
Search strategy
A search was performed in PubMed, Embase and the
Cochrane library from database inception to August 2015
with terms related to abnormal uterine bleeding and terms
for endometrial cancer or indications or methods for inves-
tigation (Appendix S1).
Selection criteria
Prospective or retrospective studies of patients with abnor-
mal uterine bleeding, where endometrial cancer or atypical
hyperplasia was an outcome, were included in the review.
Studies in populations of exclusively post-menopausal
women, and studies of mixed populations of pre and post-
menopausal women where the data could not be separated,
were excluded. Study selection was undertaken by one
reviewer.
Data collection and quality assessment
Information on study and patient characteristics and num-
bers of individuals with endometrial cancer and atypical
hyperplasia were extracted from included studies. Data was
extracted independently by two reviewers, with any dis-
agreements resolved by consensus or reference to a third
reviewer. Quality assessment was conducted by one
reviewer, examining the internal and external validity of
risk estimates. Internal validity was judged by the accuracy
of the method used to investigate for the presence of
malignancy. Where histological testing was conducted for
all women, internal validity was judged to be good. In
studies where a pathological diagnosis was not present for
all women, internal validity was also potentially good where
investigators appeared to have implemented adequate refer-
ral/treatment pathways. External validity was assessed as
the applicability of the study sample to the population of
this review i.e. women presenting in primary care with
abnormal uterine bleeding. Where studies included women
who appeared to have been included in the study because
of high suspected risk, these were judged as less applicable,
with low external validity.
Data analysis
The risk was calculated using logistic regression with robust
standard errors to account for clustering by study. Analyses
were conducted for rates of (i) endometrial cancer and (ii)
endometrial cancer and atypical hyperplasia combined.
Sensitivity analysis was conducted, including only those
studies judged to have good internal and external validity.
The risk of endometrial cancer was also estimated within
subgroups of studies defined by location (Western/non-
Western), study design (prospective/retrospective), and size
(≥100 versus <100 premenopausal women). Where studies
reported data separately for premenopausal women of dif-
ferent ages, these were included in an additional analysis
estimating the risk of endometrial cancer in women aged
<40, 40–50 and >50 years.
Results
Study characteristics
Of 2736 original articles retrieved, 125 were obtained as full
papers; 60 were excluded as indicated in Figure 1. Sixty-five
studies (n = 29 059 premenopausal women with abnormal
uterine bleeding) were included and their characteristics
and study risk of endometrial cancer are shown in
Table S1. Studies were conducted in Europe (n = 32),
North America (n = 6), Australasia (n = 2) and non-Wes-
tern countries (n = 25). Most were in populations of
women undergoing investigation exclusively for abnormal
bleeding, but some included women undergoing investiga-
tion for other indications (data for women with bleeding
problems was extracted separately). The mean age in the
majority of studies was between 40 and 50 years.
Study quality
The internal validity of studies was generally considered to
be good. In most, the majority of women had undergone
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histopathological testing and it appeared likely that the
majority of cases of malignancy were identified. Fifty-three
studies were judged to have good internal validity, but 12
were considered to be potentially less reliable. The external
validity of studies was generally considered to be lower.
Many were retrospective (n = 37), including women who
had been investigated with invasive testing such as
endometrial biopsy or dilation and curettage. The reason
for further investigation in these populations was not often
reported but where it was, the reasons were suspected risk
factors such as obesity, anovulation or previous oligomen-
orrhoea,14 older age or failed medical management.15–17
However, some studies were judged to be more externally
valid. Forty prospective studies, and retrospective studies
where not all the population had undergone invasive test-
ing, were judged to be potentially more applicable as the
population may have been more similar to women present-
ing in primary care. Twenty-five studies were judged as
having poor external validity.
Risk of endometrial cancer
Risk of endometrial cancer according to menstrual status,
based on aggregated numbers of events and individuals
across studies, is shown in Table 1. In all studies of pre-
menopausal women with abnormal uterine bleeding
(n = 65), the risk was low, at 0.33% (95% CI 0.23–0.48%,
n = 29 059; 97 cases). When data for subpopulations of
premenopausal women were separated, the risk of endome-
trial cancer was lower for women with HMB 0.11% (95%
CI 0.04–0.32%, n = 8352; 9 cases; 24 studies) than for
women with IMB 0.52% (95% CI 0.23–1.16%, n = 3109;
14 cases; 20 studies).
Risk of endometrial cancer or atypical hyperplasia
Rates for the risk of endometrial cancer or atypical hyper-
plasia are also shown in Table 1. Thirty-one studies
reported rates of atypical hyperplasia and endometrial can-
cer/atypical hyperplasia showed a combined risk of 1.31%
(95% CI 0.96–1.80, n = 15 772, 207 cases). Only five stud-
ies reported rates of atypical hyperplasia separately for
women with HMB and all reported that there were no
cases of atypical hyperplasia. No studies reported rates of
atypical hyperplasia separately for women with IMB.
Risk by age group
Twelve studies reported rates of endometrial cancer and
four studies reported rates of both endometrial cancer and
atypical hyperplasia in specific age groups (Figure 2). For
endometrial cancer alone, there was an increase with age
group but confidence intervals were wide and there were
no conclusive differences between groups: <40 years 0.33%
(95% CI 0.16–0.70%, n = 2401; 8 cases), 40–50 years
0.51% (95% CI 0.34–0.77%, n = 6662; 31 cases) and
>50 years 1.04% (95% CI 0.24–4.41, n = 277, 2 cases).
However, for the risk of endometrial cancer or atypical
hyperplasia, the increase with age group was significant:
2736 citations
125 full text 
papers reviewed
2611 Excluded on 
title/abstract
60 Excluded due to:
All participants had endometrial cancer (n = 3)
Endometrial cancer or atypical hyperplasia not 
an outcome (n = 38)
Includes indications other than AUB (16)
Exclusively post-menopausal population (n = 2)
Excluded women without pathology (n = 1)
65 Included studies
24 contained 
separate data on 
woman with HMB
20 contained 
separate data on 
woman with IMB
Figure 1. PRISMA flow diagram.
Table 1. Prevalence of endometrial cancer and atypical hyperplasia in populations of premenopausal women with abnormal uterine bleeding
Number of studies Number of cases n % Lower 95% CI Upper 95% CI
Endometrial cancer
AUB 65 97 29 059 0.33 0.23 0.48
HMB 24 9 8352 0.11 0.04 0.32
IMB 20 14 3109 0.52 0.23 1.16
AUB sensitivity analysis* 29 40 14 511 0.28 0.15 0.50
Endometrial cancer or atypical hyperplasia**
AUB*** 31 207 15 772 1.31 0.96 1.80
AUB, abnormal uterine bleeding; HMB, heavy menstrual bleeding; IMB, inter-menstrual bleeding.
*Includes only studies judged to have higher internal and external validity.
**Includes only studies reporting rates of both endometrial cancer and atypical hyperplasia.
***In five studies that reported rates of atypical hyperplasia separately for women with HMB, none reported any cases. No studies reported rates
of atypical hyperplasia separately for women with IMB.
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<40 years 0.81 (95% CI 0.56–1.17, n = 1240; 10 cases), 40–
50 years 1.99% (95% CI 1.59–2.48, n = 5131, 102 cases) and
>50 years 14.12% (95% CI 8.20–23.24, n = 85; 12 cases).
Sensitivity and subgroup analysis
In the sensitivity analysis (Table 1), including only studies
that were judged to have higher internal and external valid-
ity (n = 29) the estimated risk of endometrial cancer in all
premenopausal women was 0.28% (95% CI 0.15–0.50,
n = 14 511; 40 cases), suggesting that the findings from the
main analysis were robust. In the subgroup analysis, esti-
mates of risk were similar in subgroups defined by study
size (<100 versus ≥100), design (prospective versus retro-
spective) or location (Westernised versus non-Westernised)
(Figure S1).
Discussion
Main findings
This review aimed to estimate the risk of endometrial can-
cer and atypical hyperplasia in premenopausal women pre-
senting with abnormal uterine bleeding and to make some
judgement about whether current guidelines are appropri-
ate. Given the large numbers of women presenting in pri-
mary care, and the potential for complications, anxiety and
wasted healthcare resources in undertaking unnecessary
biopsies, estimating this risk is important. NICE use
a > 3% cancer risk to underpin screening guidance.6 Where
risk is anticipated to be higher, guidance recommends that
patients be referred for further testing. The overall esti-
mated risk of endometrial cancer or atypical hyperplasia in
premenopausal women in this review was only 1.33%, with
confidence intervals not reaching the NICE recommended
3% risk (95% CI 0.96–1.80).
The risk of endometrial cancer in women with HMB was
particularly low (0.11%, 95% CI 0.04–0.32) and no cases of
atypical hyperplasia were observed in studies of women
with HMB. The risk of endometrial cancer was slightly
higher in women with IMB (0.52%, 95% CI 0.23–1.16) and
IMB may represent a symptom of endometrial cancer. The
number of cases of atypical hyperplasia was not reported
separately for women with IMB and it was therefore not
possible to assess the overall endometrial cancer/atypical
hyperplasia risk. However, if it is assumed that risk in
women with HMB is lower than that of the whole pre-
menopausal group, it may be assumed that the risk in
women with IMB is likely to be greater than the whole pre-
menopausal group, i.e. women with IMB will have a
greater than 1.33% risk of endometrial cancer/atypical
hyperplasia. Therefore, for women with persistent IMB
who are not responding to medical management, referral
for further testing may be appropriate.
There were some data regarding the association of age
with risk of endometrial cancer and atypical hyperplasia.
There was an increase in risk for women aged 40–50 years
compared with <40 years that was significant when consid-
ering endometrial cancer and atypical hyperplasia together.
Although the numbers of studies contributing to these
analyses was very small (only four for endometrial cancer
and atypical hyperplasia) it appears likely that there is some
increase in risk associated with increased age during the
40s. The NICE guideline recommends age as a criterion for
biopsy only after all conventional medical management has
failed.12 Given that the upper confidence interval of esti-
mated risk in the 40- to 50-year age group was below the
3% risk cutoff, the NICE guidance appears justified. Due to
the current lack of data, it is not possible to identify a
specific age at which there may be an increase in risk, but
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Figure 2. Prevalence of endometrial cancer and atypical hyperplasia in pre-menopausal women with abnormal uterine bleeding in different age
groups.
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further research may help to determine an appropriate age
criteria for referral following failure of conventional medi-
cal management.
The current review did not find data on risks associated
with co-morbidities but we reviewed the literature. Muta-
tions related to HNPCC, or Lynch syndrome, are associated
with a high lifetime risk of endometrial cancer (12–44%);18
this is an important consideration, but only in this specific
and small group of women.
For other risk factors, the association appears less pro-
nounced. A recent meta-analysis showed PCOS to be a sig-
nificant risk factor for endometrial cancer (odds ratio
2.79),19 but all included studies were case-control studies
and hence this estimate is likely to be unreliable. There is
more robust evidence for other risk factors from systematic
reviews of prospective cohort studies. Higher BMI was
associated with increased risk of endometrial cancer, with a
relative risk (RR) of 1.54 for a five-point increase in BMI
and RR 1.41 in the subgroup of studies of premenopausal
women.20 For women with diabetes mellitus, risk of
endometrial cancer was higher compared with those with-
out diabetes mellitus (RR 1.89),21 and being parous as
opposed to nulliparous was estimated to decrease the risk
of endometrial cancer (RR 0.69).22
Caution is needed in relating these findings as studies
are of general populations of women, and not specifically
in women with bleeding problems. It is therefore unclear
whether the relative risks would be the same. It is also
unclear to what extent risks factors are independent or
whether they confound one another. It appears unlikely
that the risks are cumulative and treating them as such is
likely to overestimate total relative risk.
However, even without these cautions, given the low risk
of endometrial cancer, the absolute risks are likely to be
low. For example, considering BMI, for a woman present-
ing with HMB, her risk of endometrial cancer increases
from 0.11% (assuming risk found in the current review
and a 1.41 increase in risk20) to 0.16% with a five-point
increase in BMI and to 0.22% with a ten-point increase.
Strengths and limitations
This review included a large number of studies and pro-
vides a robust estimate of the risk of endometrial cancer in
premenopausal women with abnormal uterine bleeding. No
other systematic review was found and this may be the first
to undertake this type of work. It is clinically meaningful
and has direct implications for practice.
A limitation of this review is that studies predominately
included populations of women referred to secondary care
who were undergoing invasive testing (dilation and curet-
tage or endometrial biopsy) for suspicion of abnormalities
or pathology. They are therefore unlikely to reflect typical
populations of women presenting in primary care. Women
undergoing invasive testing for suspected pathology may
have a higher incidence compared with general populations
of women presenting with abnormal uterine bleeding and
these studies may thus overestimate the risk of endometrial
cancer. The findings of the review are therefore likely to be
conservative, further supporting the view that pre-
menopausal abnormal uterine bleeding confers a low risk
for endometrial cancer or atypical hyperplasia.
Another limitation of the review was the difficulty in
searching for studies. Most studies did not set out to deter-
mine rates of endometrial cancer as a primary outcome
and results are incidentally reported. It is therefore possible
that some studies were missed. However, a search strategy
was used where endometrial cancer was not specified as a
required outcome, and it appears likely that the majority of
studies with relevant data were obtained.
Interpretation
There generally appears to be a low risk of endometrial
cancer in premenopausal women and much current guid-
ance appears over-cautious. The majority of women in
studies were aged >40 years and overall risk of endometrial
cancer was only 0.33%. When cases of atypical hyperplasia
were also considered, the rate was still well below the NICE
3% threshold for cancer referrals.
HMB conferred a particularly low risk and although stud-
ies suggest that some co-morbidities increase the risk of
endometrial cancer, given the very low baseline risk associ-
ated with HMB, the absolute risk in the presence of co-mor-
bidities is likely to still be low. Guidance recommending
direct referral for biopsy in premenopausal women
>40 years10,11 or with co-morbidities11,13 therefore appears
unwarranted.
The risk associated with IMB appears to be slightly
higher. It is unclear whether the cumulative risk of
endometrial cancer and atypical hyperplasia would reach
the 3% risk NICE recommend for cancer referral but,
where medical management fails, referral of women with
IMB may be justified.
The UK NICE guidance12 is the least cautious guideline
and appears to provide a reasonable model, where women
are only considered for biopsy in the presence of persistent
IMB or, for women aged >45 years with HMB alone, fol-
lowing failure of conventional medical management. There
is currently no evidence to suggest that clinicians should
deviate from this.
Conclusion
This review demonstrates that the risk of endometrial can-
cer or atypical hyperplasia in premenopausal women with
abnormal uterine bleeding is low. Consequently, this group
of women should first undergo conventional medical
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management. In women who have failed medical manage-
ment, the presence of persistent IMB and older age may be
indicators for further investigation. The review suggests
that practice needs to change, where referral for biopsy in
premenopausal women is only in selected cases. Further
research is needed to better understand the effect of age
and the cumulative effect of co-morbidities.
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